Insulin-like growth factor receptor
Insulin-like growth factor receptors (IGFR) are transmembrane receptors which are stimulated by insulin-like growth factors (IGF). IGFR contains 2 extracellular α chains and 2 transmembranal β chains. Upon binding of IGF, a tyrosine in the β chain becomes autophosphorylated and triggers a cascade of intracellular signaling. The insulin-like growth factor 1 (IGF-1) receptor belongs to the large class of tyrosine kinase receptors. See also IGF1, Growth factors and Kinase-linked, enzyme-linked and related receptors.
Memory-Enhancement by Traditional Chinese Medicine? [3]Cognitive impairment is an emerging issue and increasing research points to the significant role of insulin-like growth factor I (IGF-I) in cognitive brain functions. IGF receptor (IGF-IR, PDB ID: 3i81, colored in darkmagenta) activation is critical for IGF-I to elicit desirable cognitive functions. Traditional Chinese medicine (TCM) ligands 3-(2-carboxyphenyl)-4(3H)-quinazolinone (orgin: Isatisin digotica, colored in green), (+)-N-methyllaurotetanine (origin: Lindera aggregate, colored in deeppink), and (+)-1(R)-Coclaurine (origin: Nelumbonucifera Gaertn, colored in salmon) showed high binding affinity towards IGF-IR at the binding site defined by the control in PDB ID: 3i81. Molecular dynamics simulation revealed that the TCM ligands were secured at the opening of the IGF-IR binding site for the duration of the MD. 3-(2-carboxyphenyl)-4(3H)-quinazolinone was stabilized by Asp1056, (+)-N-methyllaurotetanine was stabilized by Leu975 and Asp1056, and (+)-1(R)-Coclaurine was stabilized by Leu975 and Gly1055 (key residues are colored in yellow). Four different quantitative-structure activity relationship models consistently predicted bioactivity of the TCM ligands towards IGF-IR. In summary, the TCM candidates exhibit drug-like potential in both structural-based and ligand-based properties and may have potential for further applications in enhancing cognition.
| ||||||||||||
3D structures of insulin-like growth factor receptor
Updated on 22-September-2025
- IGFR I
- tyrosine kinase receptors – hIGFR I domains 1-3 31-492– human
- IGF1, Growth factors - hIGFR I kinase domain (mutant) 983-1286
- Kinase-linked, enzyme-linked and related receptors - hIGFR I kinase domain
- 3i81 - hIGFR I kinase domain + insulin receptor substrate peptide
- 3i81, 2zm3, 3d94, 3f5p, 3i81, 3lvp, 3nw5, 3nw6, 3nw7, 3lw0, 3qqu, 3o23, 4d2r, 5fxq, 5fxr, 5fxs, 5hzn - hIGFR I kinase domain + inhibitor
- 8pyj, 8pyl - hIGFR I beta chain + inhibitor
- 5u8r - hIGFR I (mutant) + antibody
- 5u8q - hIGFR I (mutant) + IGFI + antibody
- 8tan - hIGFR I 31-935 + MFRVIGF 16-79 – Cryo EM
- 6pyh - hIGFR I + IGFI – Cryo EM
- 6vwg, 6vwh, 6vwi, 6vwj - hIGFR I + IGFII – Cryo EM
- 7s8v - hIGFR I + insulin receptor – Cryo EM
- 7s0q - hIGFR I + insulin receptor + IGF I – Cryo EM
- tyrosine kinase receptors – hIGFR I domains 1-3 31-492– human
- IGFR II
- 1gqb - hIGFR II
- 2kva - hIGFR II domain 5 – NMR
- 2cnj - hIGFR II domain 11 - NMR
- 2l2a, 2m68, 2m6t - hIGFR II domains 11 (mutant) - NMR
- 2kvb - hIGFR II domain 5 + inhibitor – NMR
- 2v5n - hIGFR II domains 11-12
- 2v5o - hIGFR II domains 11-14
- 2v5p - hIGFR II domains 11-13 + IGF II
- 2l29 - hIGFR II domain 11 + IGF II - NMR
- 1gp0, 1gp3, 1e6f - hIGFR II IGF II-binding domain
- 1q25 - bIGFR II domains 1-3 – bovine
- 1syo, 1sz0 - bIGFR II domains 1-3 + mannose-6-phosphate
- 2lla - IGFR II domain 11 – short-beaked echidna - NMR
- 2l2g - IGFR II domain 11 – opossum - NMR
- 1gqb - hIGFR II